PTC Therapeutics PTCT Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Emflaza | $146.36M-29.4% | $207.23M-18.8% | $255.09M+16.8% | $218.4M+16.7% | |
| Other Products | $37.27M+0.9% | $36.95M+17.3% | $31.5M— | —— | |
| Translarna1 | $235.3M-26.7% | $321.07M-3.5% | $332.75M— | —— | |
| Translarna | -$98.63M— | —— | —— | $288.5M+22.2% | |
| Revenue by Geography | |||||
| All Other Countries Other Than Russia Brazil And United States | $168.41M-14.7% | $197.47M-17.2% | $238.51M— | —— | |
| BR | $65.66M-8.9% | $72.08M+23.0% | $58.61M— | —— | |
| RU | $100.45M-4.7% | $105.38M+22.6% | $85.97M— | —— | |
| US | $252.18M+21.7% | $207.22M-18.8% | $255.09M-33.2% | $381.86M+28.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does PTC Therapeutics break its business down?
- PTC Therapeutics (PTCT) reports revenue by product across 6 parts — Emflaza, Other Products, Sephience, Translarna1 and Translarna. Each is extracted from the segment footnotes and tracked over time.
- Where does PTC Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in PTC Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
